We offer a comprehensive suite of antibody generation platforms designed to provide high-affinity, internalizing antibodies ideal for drug conjugation. Our focus on developability, internalization, and conjugation-compatibility ensures you receive antibodies ready for downstream functionalization and therapeutic development.
Antibody Discovery
Efficient and scalable antibody production is foundational to ADC development. Whether you are screening multiple candidates or generating large-scale material for conjugation and preclinical evaluation, Aurigene offers flexible expression platforms tailored to your project timeline and stage. From rapid transient expression for early-stage ADCs to stable cell line development for consistency batches, our upstream capabilities are designed to ensure high-quality antibody supply optimized for downstream conjugation and analytical success.
Transient Expression
- Rapid antibody generation using HEK293 or CHO systems
- Ideal for early-stage ADC screening and quick turnaround
- Typical yields: 50–400 mg/L (HEK); up to 1 g/L (CHO)
- Antibodies purified via Protein A, ion exchange (if needed), and SEC
Get high-purity antibodies ready for conjugation in just 2–3 weeks.
Stable Cell Line Development
- Generation of CHO-based stable clones for long-term, scalable production
- Clone screening based on titer, growth profile, and product quality
- High-yield fed-batch process with optimization of expression vectors and media
Consistency, scalability, and control for large-scale ADC programs
Downstream Purification for Conjugation Readiness
- Platform purification using Protein A, SEC, HIC, and IEX
- Endotoxin control, buffer exchange, and low aggregation guaranteed
- Analytical QC: SDS-PAGE, SEC, endotoxin, intact mass, and reduced mass
Ensures conjugation-grade antibodies with full lot release documentation
Why Choose Aurigene for Antibody Production?
At Aurigene, our antibody production is tightly integrated with the downstream bioconjugation workflow ensuring that every batch is not just pure, but conjugation-ready. We offer flexible production formats, rapid timelines, and quality control designed specifically for the unique needs of ADC development. Whether your program needs 1 mg or 1 g, our agile team and modular facilities can scale with your project without compromising on quality or timelines.
We offer:
CHO and HEK-based systems for flexible, rapid expression
Conjugation-optimized production workflows from day one
Experienced upstream and purification scientists with ADC focus
Full characterization support: Mass, DAR, aggregation, and endotoxin
Seamless integration with conjugation, analysis, and in vitro teams
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Oligonucleotide as a novel class of therapeutic modality
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read More
HPAPI Molecule from Development to Market
The global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read More
Systematic formulation design - shorten development cost & time
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More -
Development of novel paullone-based PROTACs as anticancer agents
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market